Annalise.ai vs Behold.ai
Two chest radiograph companies separated by whether a human still reads the film. Annalise reads comprehensively across a large findings set with regulatory footprints in several markets and greater deployment maturity, and the radiologist decides every case. Behold auto reports films it classifies as high confidence normal, taking them off the worklist entirely, and publishes the peer reviewed performance numbers that autonomy demands. For a department whose backlog is normal films, Behold is doing something Annalise does not attempt and the saving is structural rather than incremental. The condition is that its false negative rate at the operating threshold has to be published, revalidated locally and monitored, because on an auto reported study nobody is ever going to catch the miss.
- Comprehensive chest radiograph coverage across a large findings set, with regulatory footprints in multiple markets and a joint venture supplying real reading volume.
- The reader retains the decision on every study, which is the conventional and lower risk configuration.
- Deployment maturity is greater, which matters for a modality where the failure is a subtle finding missed at scale.
- It removes studies from the worklist entirely by auto reporting films classified as high confidence normal, which is genuine autonomy inside a bounded task.
- The performance numbers that autonomy requires are published in peer reviewed venues, and the confidence threshold is itself the governance mechanism.
- For a service drowning in normal chest films, removing them from the queue is a different economic proposition from reading them faster.
Side by Side
| Axis | A Annalise.ai |
B Behold.ai |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
The autonomy difference sets the evidence bar: an auto reporting normal classifier needs its false negative rate at the operating threshold published and locally revalidated, because a missed finding on an auto reported film is never seen by anyone. Behold's regulatory standing is multi jurisdictional and unsettled and its corporate history complicates the identity of the contracting entity, both of which should be established before deployment. Neither publishes a security attestation or pricing, and findings counts are not comparable between them.